Replies to post #13609 on Momenta Pharmaceuticals, Inc. (MNTA)

[DFRAI]

Timing of the CA19 tests? I would imagine is standard to measure at baseline (before treatment) and at various readout points. What could be so complicated on the timing of the test?
Without necuparanib administration - would there be a benefit in CA19 results....?

Does not make sense what you are saying